Market capitalization | $44.65m |
Enterprise Value | $99.04m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.59 |
P/S ratio (TTM) P/S ratio | 0.72 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 809.03% |
Revenue (TTM) Revenue | $62.39m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
5 Analysts have issued a Atara Biotherapeutics Inc forecast:
5 Analysts have issued a Atara Biotherapeutics Inc forecast:
Dec '23 |
+/-
%
|
||
Net Profit | -276 -276 |
21%
21%
|
|
Depreciation and Amortization | 4.83 4.83 |
67%
67%
|
|
Stock Compensation | 45 45 |
16%
16%
|
|
Operating Cash Flow | -193 -193 |
29%
29%
|
|
Investments | 1.22 1.22 |
71%
71%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -194 -194 |
29%
29%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Anhco Nguyen |
Employees | 225 |
Founded | 2012 |
Website | www.atarabio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.